[go: up one dir, main page]

PE20090184A1 - Combinaciones del il-18 humana y anticuerpos monoclonales - Google Patents

Combinaciones del il-18 humana y anticuerpos monoclonales

Info

Publication number
PE20090184A1
PE20090184A1 PE2008000532A PE2008000532A PE20090184A1 PE 20090184 A1 PE20090184 A1 PE 20090184A1 PE 2008000532 A PE2008000532 A PE 2008000532A PE 2008000532 A PE2008000532 A PE 2008000532A PE 20090184 A1 PE20090184 A1 PE 20090184A1
Authority
PE
Peru
Prior art keywords
human
antigen
combinations
combination
monoclonal antibodies
Prior art date
Application number
PE2008000532A
Other languages
English (en)
Inventor
Zdenka Ludmila Jonak
Zdenka Haskova
Stephen H Trulli
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20090184A1 publication Critical patent/PE20090184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: a) UN POLIPEPTIDO (SEQ ID Nº:1) DE LA IL-18 HUMANA EN COMBINACION CON UN VEHICULO Y b) UN ANTICUERPO MONOCLONAL CONTRA UN ANTIGENO CONTRA UN ANTIGENO QUE SE EZPRESA EN LA SUPERFICIE DE UNA CELULA CANCEROSA, EL CUAL NO ES UN ANTICUERPO ANTI-CD20, DONDE EL ANTIGENO SE SELECCIONA DEL GRUPO DE CD22, CD19, HER2, HER3, EGFR, IGF-1R, AXL-1, FGFR, RECEPTORES DE INTEGRINAS, CEA, CD44 Y VEGFR. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE DIVERSOS TUMORES SOLIDOS Y LINFOMAS
PE2008000532A 2007-03-23 2008-03-24 Combinaciones del il-18 humana y anticuerpos monoclonales PE20090184A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26

Publications (1)

Publication Number Publication Date
PE20090184A1 true PE20090184A1 (es) 2009-03-22

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000506A PE20090190A1 (es) 2007-03-23 2008-03-19 Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
PE2008000532A PE20090184A1 (es) 2007-03-23 2008-03-24 Combinaciones del il-18 humana y anticuerpos monoclonales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008000506A PE20090190A1 (es) 2007-03-23 2008-03-19 Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18

Country Status (21)

Country Link
US (4) US20100196310A1 (es)
EP (3) EP2136841A4 (es)
JP (2) JP2010522239A (es)
KR (2) KR20100015798A (es)
CN (1) CN101678102A (es)
AR (2) AR065803A1 (es)
AU (2) AU2008231025A1 (es)
BR (2) BRPI0808943A2 (es)
CA (2) CA2681851A1 (es)
CL (2) CL2008000818A1 (es)
CR (2) CR10996A (es)
DO (2) DOP2009000208A (es)
EA (2) EA200970885A1 (es)
IL (2) IL200525A0 (es)
MA (2) MA31265B1 (es)
MX (2) MX2009010269A (es)
NZ (1) NZ579179A (es)
PE (2) PE20090190A1 (es)
SG (1) SG171674A1 (es)
TW (2) TW200906436A (es)
WO (2) WO2008118736A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338515A3 (en) * 2000-02-10 2011-11-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MA39909B1 (fr) 2014-04-25 2019-05-31 Pf Medicament Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MX378281B (es) 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
AU2015300006B2 (en) 2014-08-07 2018-08-30 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
WO2016126615A1 (en) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2022115946A1 (en) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists
WO2025033330A1 (ja) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 キマーゼ阻害剤と免疫療法の併用による抗腫瘍療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692536B1 (en) 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
CZ20024085A3 (cs) * 2000-06-15 2003-05-14 Smithkline Beecham Corporation Způsob přípravy fyziologicky aktivního IL-18 polypeptidu
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
EP1519959B1 (en) * 2002-02-14 2014-04-02 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
KR20040094705A (ko) * 2002-02-21 2004-11-10 듀크 유니버시티 자가면역질환에 대한 시약 및 치료 방법
EP1545587B1 (en) * 2002-09-16 2011-02-09 Agennix Incorporated Lactoferrin compositions and methods of diabetic ulcer treatment
CN101658672B (zh) * 2002-10-08 2017-09-26 免疫医疗公司 用iii类抗cea单克隆抗体和治疗剂进行联合治疗
ES2524694T3 (es) * 2002-10-17 2014-12-11 Genmab A/S Anticuerpos monoclonales humanos contra CD20
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
ATE459647T1 (de) * 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CA2534639C (en) * 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
CA2604222A1 (en) * 2005-04-18 2006-10-26 Novo Nordisk A/S Il-21 variants
JP2009501913A (ja) * 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
JP2009543810A (ja) * 2006-07-13 2009-12-10 ザイモジェネティクス， インコーポレイテッド インターロイキン２１およびチロシンキナーゼ阻害剤の併用治療の方法
EP2059253A4 (en) * 2006-09-14 2011-09-14 Univ Pennsylvania MODULATION OF T LYMPHOCYTES REGULATORS BY HUMAN IL-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
US20080274078A1 (en) 2008-11-06
EP2136841A2 (en) 2009-12-30
EP2129398A1 (en) 2009-12-09
WO2008118733A3 (en) 2008-11-27
AR065803A1 (es) 2009-07-01
WO2008118733A2 (en) 2008-10-02
US20100196310A1 (en) 2010-08-05
BRPI0808943A2 (pt) 2014-08-26
SG171674A1 (en) 2011-06-29
AU2008231114A1 (en) 2008-10-02
CL2008000842A1 (es) 2008-10-17
AR065818A1 (es) 2009-07-01
CL2008000818A1 (es) 2008-09-26
WO2008118736A1 (en) 2008-10-02
BRPI0809079A2 (pt) 2019-03-06
US20100111945A1 (en) 2010-05-06
TW200904469A (en) 2009-02-01
EA200970885A1 (ru) 2010-02-26
TW200906436A (en) 2009-02-16
MA31265B1 (fr) 2010-03-01
AU2008231025A1 (en) 2008-10-02
MX2009010269A (es) 2009-10-12
EP2129398A4 (en) 2010-04-21
DOP2009000220A (es) 2009-10-31
CA2681851A1 (en) 2008-10-02
CR11075A (es) 2010-03-22
PE20090190A1 (es) 2009-03-22
JP2010522200A (ja) 2010-07-01
CN101678102A (zh) 2010-03-24
CA2681827A1 (en) 2008-10-02
US20090035258A1 (en) 2009-02-05
MA31264B1 (fr) 2010-03-01
MX2009010271A (es) 2009-10-12
NZ579179A (en) 2011-12-22
DOP2009000208A (es) 2010-03-31
CR10996A (es) 2009-11-12
IL200525A0 (en) 2010-04-29
EA200970884A1 (ru) 2010-04-30
IL200863A0 (en) 2010-05-17
JP2010522239A (ja) 2010-07-01
EP2338514A1 (en) 2011-06-29
EP2136841A4 (en) 2010-07-07
KR20100015798A (ko) 2010-02-12
KR20100014530A (ko) 2010-02-10

Similar Documents

Publication Publication Date Title
PE20090184A1 (es) Combinaciones del il-18 humana y anticuerpos monoclonales
PE20180798A1 (es) Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
MX337600B (es) Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20211299A1 (es) Receptores de antigeno quimericos dirigidos a cd70
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
NZ596317A (en) Antibodies directed to her-3 and uses thereof
ATE486610T1 (de) Anti-glypican-3-antikörper
PE20110593A1 (es) Anticuerpos multiespecificos
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
SA520411849B1 (ar) أجسام مضادة ومتقارنات جسم مضاد مع عقار نوعية من أجل cd123 واستخداماتها
EA201790280A1 (ru) Ror1-(ntrkr1)-специфические химерные антигенные рецепторы для иммунотерапии рака
PL1883698T5 (pl) Przeciwciała monoklonalne i jednołańcuchowe fragmenty przeciwciał skierowane przeciw antygenom błonowym specyficznym dla powierzchni komórek prostaty
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
WO2004005470A3 (en) Antibodies to non-shed muc1 and muc16, and uses thereof
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
WO2007123661A3 (en) Treatment of tumors expressing mutant egf receptors
EP3009454A3 (en) Antibodies specific to cadherin-17
WO2016022939A8 (en) Human monoclonal antibodies specific for 5t4 and methods of their use
MY181960A (en) Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
EA202192413A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ
ATE473279T1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135

Legal Events

Date Code Title Description
FC Refusal